Kornimate/medical-research-clean huggingface dataset:
yoga, aerobic and stretching exercise effects on neurocognition

Conditions: Aging; Cognitive Decline

Summary: the investigators propose to conduct a 6-month 3-arm randomized controlled exercise trial among older adults to compare the efficacy of yoga with aerobic exercise and stretching-toning exercises on cognitive function, brain structure and function, cardiorespiratory fitness, functional fitness, and inflammatory and molecular markers. using a single-blind, three arm randomized control trial, 168 older adults ages 55-79 will be assigned to either: a hatha yoga group, an aerobic exercise group or an active stretching and toning control group. the groups will engage in hour-long group exercise sessions 3x/week. a comprehensive neurocognitive test battery, brain imaging, cardiovascular fitness test, and a blood draw will take place at baseline; end of the 6-month intervention, and at 12-month follow-up. the proposed work will examine the relationship between yoga training and improved cognitive functioning as well as identify neurobiological correlates as potential mechanisms of action through which yoga training exerts its effect on cognitive function. covid-19 precautions: due to covid-19, all exercise sessions will be conducted live via zoom video-conferencing such that 1/3rd of the participants in each group will exercise in person with the research staff at uiuc campus once a week while the remaining 2/3rd will tune in via zoom


Eligibility criteria:
inclusion criteria: * 55-79 years of age at study enrollment * tics-m score of 32 or higher * no current or past diagnosis of mild cognitive impairment or dementias * low-active (≤ 2 days of 30 minutes of structured exercise/week) * physician's consent to participate in vo2max testing and the exercise program * ambulatory * absence of health conditions that may be exacerbated by exercise * good or corrected vision and hearing * no mri contraindications (e.g. metal or implanted devices in the body) * right-handed * intention to remain in the champaign-urbana area over the study duration exclusion criteria: * below 55 or above 79 years of age at study enrollment * tics-m score of 31 or lower * current or past diagnosis of mild cognitive impairment or dementias * high-active (3 or more days of 30 minutes of structured exercise/week) * physician's non-consent to participate in vo2max testing and the exercise program * non-ambulatory (use of wheelchairs or walkers) * presence of health conditions that may be exacerbated by exercise * poor vision and hearing * mri contraindications (e.g. metal or implanted devices in the body) * left-handed * plans to travel outside of champaign-urbana area during the study
hydrolyzed egg and tolerance induction

Conditions: Allergy

Summary: the aim of this trial is to assess the effect of hydrolyzed egg orally administered on oral tolerance induction to egg in children allergic to egg as compared to a placebo.


Eligibility criteria:
inclusion criteria: * child of any ethnicity aged between 12 and 66 months at the time of enrolment * positive skin prick test (spt) to egg white within the last 3 months * either positive oral challenge or convincing history, defined as an immediate (\ 0.35 ku/l) for at least one of the following: egg, egg white, ovalbumin, ovomucoid, within the last 12 months * having obtained his/her signed legal representative's informed consent. exclusion criteria: * history of severe anaphylaxis to egg * significant pre-natal and/or post-natal disease * child on systemic drugs (e.g. antihistamines, beta-agonists, ace-inhibitors) according to half-life at time of enrolment * congenital illness or malformation that may affect normal growth (especially immunodeficiency) * child whose parents / caregivers cannot be expected to comply with treatment * child currently participating in another interventional clinical trial

Keywords: allergy egg
efficacy study of lisdexamfetamine to treat bipolar depression

Conditions: Bipolar Depression

Summary: the specific aim of this study is to evaluate the efficacy and tolerability of a stimulant (lisdexamfetamine) in the adjunctive treatment of bipolar disorder.


Eligibility criteria:
inclusion criteria: * men and women, through the ages of 18 and 55 years, inclusive. exclusion criteria: * women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. * subjects who are displaying clinically significant homicidality or suicidality * clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. subjects should be biochemically euthyroid to enter the study.
effectiveness of play interventions on anxiety among hospitalized children

Conditions: Anxiety

Summary: the study evaluates the effectiveness of play interventions on anxiety among hospitalized children in selected hospital of yamuna nagar, haryana. quasi experimental approach was adopted. 60 (30 in experimental and 30 in comparison)hospitalized children were selected by purposive sampling technique.hospitalized children in experimental group were provided play interventions whereas the children in comparison group received only usual medical and nursing care.

tsetting was selected by randomization (by lottery method) first selected two rooms from general pediatric wards were coded as e1 (experimental 1) and e2 (experimental 2) whereas next two were coded as c1 (comparison 1) and c2 (comparison 2). from the selected settings 60 subjects (30 in experimental and 30 in comparison) were selected by purposive sampling technique. assessment of anxiety (pre-test) of the hospitalized children admitted in aashirwad hospital was done in experimental group and comparison group on 1st day. in experimental group after taking pretest play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. the play interventions were administered for 1 hour daily from day 1 to day 5 whereas in comparison group all the subjects were given usual general nursing and medical care for continuous 5 days. no intervention was administered to the comparison group. posttest anxiety was assessed on 5th day. intervention to the control group was given after the accomplishment of post test for ethical consideration.

Eligibility criteria:
inclusion criteria: * the study include hospitalized children who were: 1. aged 6-12 yrs. admitted in the pediatric general medical unit. 2. anxious due to hospitalization. 3. willing to participate in the study. 4. alert, oriented, comprehend and able to speak and understand hindi language. exclusion criteria: the study exclude hospitalized children who were: * 1. treated as outpatient

Keywords: play interventions, anxiety
a trial in mini-invasive pilonidal sinus disease surgery

Conditions: Pilonidal Disease

Summary: pilonidal sinus disease is a chronic acquired disease leading to significant morbidity and healthcare costs in young man and women. despite different treatment methods, the disease relatively often leads to postoperative complications and recurrence.(8). advantages of mini-invasive techniques include: quicker recovery and earlier return to work and high patient satisfaction. randomized studies are rare and this applies especially to newer mini-invasive techniques. the purpose of the investigators prospective study is to randomly compare the mini-invasive laser ablation technique to the mini-invasive fibrin glue treatment in pilonidal sinus disease surgery.

this is a multicenter study comparing two mini-invasive treatmnet options in pilonidal sinus disease. the study is carried out in four hospitals in uusimaa county of finland (jorvi hospital, porvoo hospital, lohja hospital and hyvinkää hospital). patients, who are 18 or above, with a symptomatic primary pilonidal sinus disease are eligible for the study. on the day of surgery, the patient is randomly assigned to one of the two surgery groups. the main variable of our study is the healing rate at 2 months after surgery. other variables to be studied are: postoperative complications, length of sick leave, time for returning to everyday life, recurrence rate and the effects of psd and psd surgery on the patient's quality of life. a cost analysis will be performed. risk factors such as overweight, pubic hair, smoking and associated diseases such as diabetes will also be analyzed. according to the power calculation, the investigators need 94 patients in each group to ensure the success of the study.

Eligibility criteria:
inclusion criteria: * primary pilonidal sinus disease * age 18 and above exclusion criteria: * recurrent pilonidal sinus disease * age under 18 * inability to understand finnish or swedish (the questionnaires are in finnish and swedish only, the two official languages of finland)

Keywords: pilonidal sinus disease laser ablation fibrine glue randomized trial prospective study
study to evaluate an oxaliplatin-based chemotherapy in patients with resistant or relapsing non-hodgkin lymphoma.

Conditions: Non-Hodgkin Lymphoma

Summary: evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of oxaliplatin, gemcitabine, rituximab and dexamethasone for treatment of patients with refractory or relapsing non-hodgkin lymphoma.


Eligibility criteria:
inclusion criteria: 1. patients 18 years or above at the time of inclusion. 2. documented cd20+ nhl, refractory or relapsing after first line chemotherapy. 3. no contraindication to oxaliplatin, gemcitabine, dexamethasone or rituximab. exclusion criteria: 1. other types of non-hodgkin lymphoma 2. pregnancy and lactation. 3. patient unable to give written informed consent. 4. contra-indication ou intolerance to any of the components of the rgdox chemotherapy.
stn-ttis modulates parkinson motor symptoms with and without medications

Conditions: Parkinson Disease

Summary: the goal of this clinical trial is to evaluate the immediate effects of individualized 130 hz stn-ttis(subthalamic nucleus - transcranial temporal interference stimulation)on motor symptoms in early-to-mid-stage pd patients during both medication "on" and "off" states. the main questions it aims to answer are: 1. does the therapeutic effect of stn - ttis relate to medication? 2. the degree of improvement in motor symptoms of parkinson's disease patients after stn - ttis therapy under different medication conditions. researchers compared the mds - updrs - iii improvement scores of ttis therapy in the "on" and "off" medication phases to see if ttis could work of independently medication. 1. visit the clinic once every 1 weeks for therapy and test. 2. record their symptoms and scores.

this clinical trial aims to explore whether individualized 130 hz subthalamic ttis can improve motor symptoms of pd independently of medication. . each participant underwent two separate 20-minute sessions of individualized 130 hz stn-ttis: one during medication "on" (defined as stable dopaminergic medication effect) and one during medication "off" (after ≥12 hours withdrawal of dopaminergic medications). the order of sessions was randomized with at least 7 days washout between sessions to avoid carryover effects. and mds - updrs - iii scales are assessed before and after each treatment.

Eligibility criteria:
inclusion criteria: * mds diagnosis of primary parkinson's disease * hoehn \& yahr stage \< 3 * antiparkinsonian drugs remained unchanged in the past four weeks and dosage remained unchanged during the study exclusion criteria: * presence of neurological disorders that may affect the study (e.g., traumatic brain injury) * history of antipsychotics, antidepressants, or dopamine modulators other than pd drugs * metal devices in the head or heart (e.g., deep brain stimulators, pacemakers) * unstable vital signs

Keywords: subthalamic nucleus transcranial temporal interference stimulation mds-updrs-ⅲ
optimization of vns in epileptic patients to induce cardioprotection

Conditions: Epilepsy; Sudden Cardiac Death

Summary: this study is a non-randomized, prospective study in patients with a diagnosis of epilepsy and previously implanted fda approved vagus nerve stimulation (vns) devices. the goal of this clinical investigation is to evaluate the effects of adjusting vagus nerve stimulation parameters to engage cardioprotective effects.

epilepsy patients are at increased risk for sudden cardiac death. mechanisms behind this predisposition is poorly understood but parasympathetic dysfunction is heavily implicated. vagus nerve stimulation (vns) protocols currently set for seizure management are poorly optimized for cardioprotection, therefore this patient population presents a unique opportunity to assess vns control of cardiac function, when vns is appropriately titrated for cardiac and seizure benefit. this study will enroll 12 patients with a diagnosis of epilepsy and previously implanted fda approved vns devices. the study will last up to 9 weeks and the patient will undergo changes to their vns settings during autonomic testing and cardiopulmonary testing.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of refractory epilepsy and implanted with a vns device or are scheduled to be implanted with a vns device. * 18 years of age or older * subjects must demonstrate willingness and ability to comply with study requirements exclusion criteria: * other implantable neuromodulatory device (e.g., brain stimulator) * treatment with cholinergic or anticholinergic medication in the past month * pre-existing cardiac arrhythmia or presence of cardiac pacemaker/defibrillator * history of dysautonomias * history of vasovagal syncope * progressive neurological diseases other than epilepsy * women that are pregnant * cognitive or psychiatric deficit that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments

Keywords: vagus nerve stimulation (vns) neuromodulation autonomics
vip - vascular infection project

Conditions: Aortitis; Vascular Graft Infection; Blood Vessel Prosthesis; Infections

Summary: constitution of a prospective multicentric observational database to study vascular infections, both native, especially aortitis, and vascular graft and endograft infections. clinical and paraclinical data on medical, surgical, anesthetic and intensive care management will be collected in order to better characterize these infections

vascular infections are rare but severe, burdened by high morbi-mortality and recurrence rates. however, many questions remain regarding their management which is still not consensual, both surgical and medical management. the term "vascular infections" encompasses vascular graft and endograft infections, as well as infections of native arteries and the aorta. for vascular graft infections, the optimal surgery is to remove the infected graft before vascular reconstruction with a new graft, either synthetic or biologic. however, some patients are too fragile to undergo surgery and might then benefit from an endovascular graft, an abscess drainage or no surgery at all, only medical treatment. for native arterial infections, surgery is often required to remove the infected arterial wall before vascular reconstruction. however, some patients cannot be operated on and might also benefit from an endovascular surgery. in these two vascular infections, the ideal anti-microbial treatment is uncertain, whether it pertains to the duration of therapy, the type of molecules, or their number. all of these medical and surgical factors may impact the prognosis of patients and should be collectively assessed in order to determine the best strategy for enhancing their outcomes.

Eligibility criteria:
inclusion criteria: * ≥ 18 years-old; * all patients with a vascular infection, either native (aortitis, arteritis) or prosthetic (vascular graft, endograft and/or stent), * oral consent exclusion criteria: * patient under legal protection

Keywords: vascular graft and endograft infections infectious aortitis infectious arteritis
neurofeedback-enhanced mindfulness meditation in traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: spaulding rehabilitation hospital is conducting a research study evaluating the effectiveness of the brain-training product, muse, an eeg-guided neurofeedback device designed to assist in cultivating a relaxed, attentive state of mind during meditation. the investigators study aims to evaluate whether such a tool could be useful in treating persistent traumatic brain injury symptoms such as inattention, impulsivity, irritability, or dysregulated mood.

twenty subjects in total will participate in this study. subjects will be randomized to focused-attention meditation training with or without the neurofeedback device, muse. subjects will be asked to practice \~10 min of daily meditation for 6-8 weeks. neuropsychological testing will be performed at the beginning of the study and after six weeks of training. at this time point, those randomized to the non-muse group will be given a device and asked to train for an additional two weeks. at the conclusion of the study, all subjects will also undergo a brief telephone or in-person exit interview regarding their experiences using the muse device. primary endpoint: change in neurobehavioral symptom inventory secondary endpoints: change in the following: wechsler adult intelligence scale-iv digit span and symbol-digit coding, trail-making test, beck anxiety inventory, beck depression inventory, cognitive and affective mindfulness scale-revised, percentage of eeg activity associated with alpha, beta, or theta activity.

Eligibility criteria:
inclusion criteria: 1. history of mild-moderate traumatic brain injury 2. impaired attention or concentration 3. \>1 year since traumatic brain injury 4. ability to participate in neurofeedback and mindfulness meditation 5. daily access to a smart phone 6. on stable dosage of neuropsychological medications with no significant changes planned for the duration of the study 7. no prior history of a meditation practice exclusion criteria: 1. severe mental illness or psychological symptoms (severe depression, suicidality, disabling anxiety, ptsd, psychosis, dissociation) 2. significant pre-morbid learning disability 3. current or recent (in past year) history of significant drug or alcohol abuse 4. medical illness severe enough to result in an attentional disorder 5. neurodegenerative disease 6. non-fluency in english.

Keywords: traumatic brain injury
the alzheimer's disease therapy with neuroaid (athene) study

Conditions: Alzheimer Disease

Summary: mlc601 (neuroaid) is a traditional chinese medicine (tcm) having neuroprotective and neuroproliferative properties in cellular and animal models of brain injury. it contains 9 herbal and 5 non-herbal components. mlc901 (neuroaid ii), a simplified formula of mlc601, containing only the 9 herbal components yet showing the same efficacy has become available. this study is carried out to find out if neuroaid ii (mlc901) is safe to be taken together with other established medicines for alzheimer's disease and whether neuroaid ii (mlc901) helps in slowing down the alzheimer's disease progression. this study will be a 6-month randomized, double-blind, placebo-controlled trial, followed by an open extension study in which all subjects who completed the main 6 month trial (irrespective of treatment allocation) will be offered open-labelled mlc901 for another 6 months.


Eligibility criteria:
inclusion criteria: * male or female, age ≥50 years * diagnosed with probable ad according to nincds-adrda criteria, * mmse score of 10 to 24, * receiving the same achei or memantine for the past 6 months prior to screening and on a stable dose for the past 4 months (stable dose is defined as 5 to 10mg/day for donepezil, 3, 4.5 or 6 mg twice daily for rivastigmine capsules, 4.6 or 9.5 mg for rivastigmine transdermal patch once daily, 8 or 12 mg twice daily for galantamine tablets, 16 to 24 mg once daily for galantamine capsules xl, 10 mg od or 10 mg bd for memantine) * patient or legal representative is able to provide informed consent exclusion criteria: * patients receiving any investigational product within 60 days or 5 half-lives prior to screening * any serious medical or psychiatric condition which in the investigator's judgement may jeopardize the patient by his/her participation in this study or may hamper his/her ability to perform and complete procedures required in the study.
development & evaluation of pneumatic artificial muscle(pam) for patients with ankle foot orthosis(afo)

Conditions: Orthopedic Disorder

Summary: pneumatic artificial muscles (pams), inspired by the structure and function of natural muscles, offer a lightweight and adaptable solution compared to traditional rigid ankle foot orthosis(afos).

the development process involves design optimization to ensure proper, fit, functionality and durability. researchers utilize advanced materials and manufacturing techniques to create pams that mimic the natural movement of the ankle joint while providing sufficient support and flexibility. evaluation of pams involves rigorous testing in both laboratory settings and real world environments. bio-mechanical analysis assesses the performance of pams during various activities such as walking, running and stair negotiation. critical trails involving patients with afos provide valueable feedback on usability, comfort and overall satisfaction. additionally, long-term studied monitor the durability and reliability of pams over extended periods of use. overall, the development and evaluation of pams for patient with afos represent a significant advancement in assistive technology. by offering a more natural and adaptive solution for gait assistance, pams enhance mobility, independence and quality of life for individuals with mobility impairments.

Eligibility criteria:
inclusion criteria: * diagnosis of droop foot * ability to tolerate pneumatic pressure * sufficient muscle strength activation exclusion criteria: * allergy to materials used in device fabrication * severe muscle weakness preventing activation * uncontrolled hypertension, pregnancy.